Utility of the neutrophil/lymphocyte ratio for predicting malignancy risk and prognosis in patients with dermatomyositis

Clin Exp Dermatol. 2020 Jun;45(4):471-473. doi: 10.1111/ced.14136. Epub 2019 Dec 16.

Authors

A A Galadari¹, L D Sun², A P Fernandez^{1

3}

Affiliations

¹ Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA.
² Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
³ Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.

PMID: 31692021
DOI: 10.1111/ced.14136

No abstract available

Publication types

Letter

MeSH terms

Case-Control Studies
Dermatomyositis / blood*
Dermatomyositis / complications*
Dermatomyositis / pathology
Female
Humans
Leukocyte Count / methods
Leukocyte Count / statistics & numerical data*
Lymphocytes / pathology
Male
Middle Aged
Neoplasms / diagnosis*
Neoplasms / mortality
Neutrophils / pathology
Predictive Value of Tests
Prognosis
Retrospective Studies
Risk Assessment